Could These 2 Challenges Derail the AstraZeneca Vaccine?

1 min read

AstraZeneca (NASDAQ: AZN) has had a rough couple of weeks. Several European countries including France and Germany suspended use of the company’s coronavirus vaccine. They cited risk of dangerous blood clots. But AstraZeneca’s situation improved in recent days. The countries reversed their decisions — and resumed vaccinations with the AstraZeneca product. In more good news, AstraZeneca reported positive results from its phase 3 U.S. trial. The company now says it’s preparing to request Emergency Use Authorization (EUA) in the U.S.

But two elements may upset the AstraZeneca vaccine’s future in the U.S. market. Let’s take a closer look at each — and what all of this means for investors in this big pharma stock.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Worried About Another Crash? Buy This Stock

Next Story

2 Top Dividend Stocks for a Better Retirement

Latest from Blog